ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill.

There are no therapies approved for vascular cognitive impairment. Multiple clinical trials have evaluated AD drugs, such as cholinesterase inhibitor donepezil and NMDA receptor antagonist memantine, in the indication. But researchers abandoned these repurposing attempts because the compounds did not consistently treat neuropsychiatric symptoms or improve the functional ability in patients. ...